A single blind randomized controlled clinical trial of Munditika churna adjuvant Chinna kwath in the management of vatarakta with special reference to Gout
DOI:
https://doi.org/10.47552/ijam.v13i4.3055Keywords:
Vatarakta, Gout, Munditika Churna, Chinna Kwath, Amrutadi KwathAbstract
Kayachikitsa is First branch of Ashtang ayurveda described by Vagbhatacharya. Samhitas like Charak Samhita, Shushrut, Vaghbhat Samhita etc. Vatarakta is described as a disease and symptoms also.
Vatarakta is a Sammurchana Janit (combined) Vyadhi of Vata and Rakta. The aggravated Vata is being obstructed in its passage by Dushit Rakta. This Vata again vitiates the whole Rakta. This condition is known as Vatarakta. It can be corelated to the Gout disease in modern science due to similar sign and symptoms. Munditika Churna has been mentioned in Chakradutta and Bhaishajyaratnavali is effective in the management of Vatarakta and thus selected as a trial drug. Amrutadi Kwath Previously tested drug is selected for control group.
Aim: To evaluate the clinical efficacy of Munditika Churna Adjuvant Chinna Kwath in Management of Vatarakta w.s.r. to Gout. Materials and Method: A total 70 patients of the age group 20-70 years presenting with signs and symptoms of Vatarakta w.s.r Gout were selected randomly from OPD of the department of Kayachikitsa. The 35 patients of trial group were treated with Munditika Churna Adjuvant Chinna Kwath and 35 patients of control group were subjected to Amrutadi Kwath. Results: Munditika Churna Adjuvant Chinna Kwath is effective on Vatarakta. Conclusion: Munditita Churna is an effective, safe and potent treatment of Vatarakta w.s.r. to Gout.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 International Journal of Ayurvedic Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
The author hereby transfers, assigns, or conveys all copyright ownership to the International Journal of Ayurvedic Medicine (IJAM). By this transfer, the article becomes the property of the IJAM and may not be published elsewhere without written permission from the IJAM.
This transfer of copyright also implies transfer of rights for printed, electronic, microfilm, and facsimile publication. No royalty or other monetary compensation will be received for transferring the copyright of the article to the IJAM.
The IJAM, in turn, grants each author the right to republish the article in any book for which he or she is the author or editor, without paying royalties to the IJAM, subject to the express conditions that (a) the author notify IJAM in advance in writing of this republication and (b) a credit line attributes the original publication to IJAM.
